– USA, CA – Lyell Immunopharma, Inc. (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of the Board of Directors.
“First and foremost, we are thankful that Rick is in great health, and we are excited to have him resume his active engagement with Lyell. In addition to his role as Chair of Lyell’s Board of Directors, we will also continue to benefit from Rick’s scientific guidance through his continued engagement with our scientists and leadership team,” said CEO, Liz Homans.
“Lyell and our mission of developing curative cell therapies for solid tumors represents the culmination of a long personal journey that inspires and motivates me, and I’m delighted to resume my role as Chair of the Board as the Company is advancing multiple programs into clinical trials,” said Board Chair, Dr. Rick Klausner. “On behalf of the entire Board, I want to thank Cathy Friedman for her leadership of the Board during the past two months.”
About Lyell Immunopharma, Inc.
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable, and curative responses to adoptive T cell therapy: T cell exhaustion and lack of durable stemness, which includes proliferative capacity, ability to self-renew, and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, California, and Seattle and Bothell, Washington.
For more information: https://lyell.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
